Table 3.
Multivariate analyses for non-relapse mortality, disease-free survival, and overall survival RR, relative risk; CI, confidence interval
| Non-Relapse Mortality | Disease-Free Survival | Overall Survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variables | N | RR (99% CI) | P-Value | Overall P-Value | RR (99% CI) | P-Value | Overall P-Value | RR (99% CI) | P-Value | Overall P-Value |
| BSI | ||||||||||
| No BSI | 4,472 | 1.00 | <0.0001 | 1.00 | <0.0001 | 1.00 | <0.0001 | |||
| VEP | 1,493 | 1.82 (1.63–2.04) | <0.0001 | 1.24 (1.15–1.34) | <0.0001 | 1.36 (1.26–1.47) | <0.0001 | |||
| LEP | 824 | 2.46 (2.05–2.96) | <0.0001 | 1.53 (1.35–1.74) | <0.0001 | 1.83 (1.58–2.12) | <0.0001 | |||
| BOTH | 339 | 2.29 (1.87–2.81) | <0.0001 | 1.49 (1.30–1.71) | <0.0001 | 1.66 (1.43–1.94) | <0.0001 | |||
| Age at HCT, years | ||||||||||
| ≤20 | 1,423 | 1.00 | <0.0001 | 1.00 | 1.00 | <0.0001 | ||||
| 21–40 | 1,439 | 1.75 (1.44–2.11) | <0.0001 | 1.28 (1.13–1.45) | 0.0001 | <0.0001 | 1.40 (1.23–1.60) | <0.0001 | ||
| 41–50 | 1,125 | 1.98 (1.57–2.51) | <0.0001 | 1.35 (1.20–1.52) | <0.0001 | 1.56 (1.36–178) | <0.0001 | |||
| 51–60 | 1,641 | 2.17 (1.74–2.71) | <0.0001 | 1.44 (1.25–1.66) | <0.0001 | 1.76 (1.54–2.02) | <0.0001 | |||
| >60 | 1,500 | 2.52 (2.00–3.10) | <0.0001 | 1.59 (1.36–1,86) | <0.0001 | 2.02 (1.76–2.33) | <0.0001 | |||
| KPS at HCT | ||||||||||
| ≥90 | 4,765 | 1.00 | 0.0010 | 1.00 | 0.0018 | 1.00 | 0.0001 | |||
| <90 | 2,230 | 1.18 (1.05–1.32) | 0.0039 | 1.18 (1.08–1.30) | 0.0005 | 1.20 (1.10–1.31) | <0.0001 | |||
| Missing | 133 | 1.38 (1.09–1.74) | 0.0067 | 1.14 (0.94–1.38) | 0.1978 | 1.20 (0.99–1.44) | 0.0574 | |||
| Disease-Disease stage variable | ||||||||||
| AML/ALL Early | 2,961 | 1.00 | <0.0001 | 1.00 | <0.0001 | 1.00 | <0.0001 | |||
| AML/ALL Intermediate | 1,542 | 1.06 (0.92–1.23) | 0.4336 | 1.17 (1.08–1.26) | 0.0001 | 1.17 (1.08–1.26) | 0.0002 | |||
| AML/ALL Advanced | 1,039 | 1.27 (1.06–1.53) | 0.0100 | 2.06 (1.89–2.25) | <0.0001 | 2.07 (1.88–2.27) | <0.0001 | |||
| MDS Early | 606 | 1.32 (1.10–1.58) | 0.0027 | 0.87 (0.78–0.96) | 0.0087 | 1.00 (0.87–1.14) | 0.9747 | |||
| MDS Advanced | 939 | 1.44 (1.24–1.68) | <0.0001 | 1.20 (1.10–1.32) | 0.0001 | 1.31 (1.19–1.44) | <0.0001 | |||
| Missing | 41 | 1.48 | 0.1703 | 1.28 (0.82–1.99) | 0.2831 | 1.25 (0.83–1.88) | 0.2955 | |||
| HCT-CI | ||||||||||
| 0 | 3,070 | 1.00 | 0.0012 | 1.00 | 0.0003 | 1.00 | <0.0001 | |||
| 1–2 | 1,872 | 1.09 (0.95–1.24) | 0.2121 | 1.06 (0.97–1.15) | 0.1914 | 1.07 (0.98–1.17) | 0.1097 | |||
| ≥3 | 2,044 | 1.27 (1.12–1.43) | 0.0001 | 1.14 (1.06–1.23) | 0.0004 | 1.21 (1.12–1.31) | <0.0001 | |||
| Missing | 142 | 1.05 (0.69–1.59) | 0.8137 | 0.78 (0.62–0.98) | 0.0302 | 0.78 (0.61–0.99) | 0.0453 | |||
| Donor/recipient HLA match | ||||||||||
| HLA-identical siblings | 1,990 | 1.00 | <0.0001 | 1.00 | <0.0001 | 1.00 | <0.0001 | |||
| 8/8 unrelated | 2,302 | 1.26 (1.09–1.45) | 0.0017 | 0.97 (0.90–1.06) | 0.5015 | 1.03 (0.95–1.13) | 0.4696 | |||
| ≤7/8 unrelated | 704 | 2.12 (1.78–2.53) | <0.0001 | 1.22 (1.09–1.36) | 0.0007 | 1.31 (1.16–1.48) | <0.0001 | |||
| Cord blood | 1,834 | 2.15 (1.83–2.53) | <0.0001 | 1.23 (1.09–1.38) | 0.0007 | 1.46 (1.29–1.64) | <0.0001 | |||
| Other | 298 | 1.60 (1.28–2.02) | <0.0001 | 1.15 (0.97–1.37) | 0.1040 | 1.26 (1.04–1.52) | 0.0161 | |||
| Conditioning regimen intensity | ||||||||||
| Myeloablative | 1.0000 | <0.0001 | ||||||||
| RIC/NMA | 1.24 (1.12–1.37) | |||||||||
| Donor/Recipient CMV status | ||||||||||
| −/− | 2,089 | 1.00 | 0.0035 | 1.00 | 0.0032 | |||||
| Any positive | 4,925 | 1.26 (1.10–1.43) | 0.0008 | 1.13 (1.05–1.22) | 0.0008 | |||||
| Missing | 114 | 1.11 (0.75–1.65) | 0.6035 | 1.07 (0.86–1.34) | 0.5438 | |||||
| Year of HCT | ||||||||||
| 2008–2009 | 1.00 | 0.0046 | ||||||||
| 2010–2012 | 0.91 (0.85–0.97) | 0.0046 | ||||||||